Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Eligible patients will be assigned to one of three cohorts based on their cancer type. Patients with metastatic melanoma will receive 240mg intravenous Toripalimab followed by YH003 every 21-day cycle. Patients with unresectable/metastatic pancreatic ductal adenocarcinoma will receive YH003 with either Toripalimab (at a fixed dose of 240mg) or standard chemotherapy(Nab-paclitaxel and gemcitabine).